Tomorrow in Islamabad, the Pakistan–China B2B Investment Conference kicks off, bringing together over 450+ firms to forge the Sino-Pak Pharma Alliance. With the support of DRAP, BOI, and SIFC, this summit isn’t just about discussions—it is about immediate, project-driven results. Dedicated on-site regulatory desks will be active to instantly fast-track licensing and joint venture approvals, […]
Stronger together for a healthier tomorrow. Read More »
A new era of healthcare transparency begins. The Drug Regulatory Authority of Pakistan (DRAP) has established critical regulatory timelines to safeguard public health: The Pakistan Pharmaceutical Manufacturers Association (PPMA) strongly welcomes these landmark regulatory milestones, standing united with DRAP in this definitive victory for national patient safety and pharmaceutical innovation.
DRAP Mandates 2D Barcodes & Syringe Upgrades Read More »
Under the newly announced Federal Budget 2026-27, the government has officially exempted customs duties on critical cancer-related Active Pharmaceutical Ingredients (APIs). This public health relief will significantly reduce manufacturing costs and make life-saving cancer treatments much more affordable across Pakistan.
Budget 2026-27: Customs Duty Removed on Cancer APIs Read More »
Pakistan Pharmaceutical Manufacturer Association (PPMA) was established on January 26, 1961, and registered as the sole representative of the pharmaceutical industry on July 18, 1961.
